Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized, Three-Armed, Open-Label, Parallel-Group, Non-Inferiority Trial to Compare the Immunogenicity and Safety of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen) in Children Aged 5 to <12 Years and 12 to <18 Years With Adults Aged 18 to 40 Years

NCT05231590 is registered in ClinicalTrials.gov with Cinnagen as lead sponsor.

NCT NCT05231590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05231590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized, Three-Armed, Open-Label, Parallel-Group, Non-Inferiority Trial to Compare the Immunogenicity and Safety of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen) in Children Aged 5 to <12 Years and 12 to <18 Years With Adults Aged 18 to 40 Years
Lead sponsor
Cinnagen
Phase
Phase 3
Overall status
Completed
Start date
February 23, 2022
Completion date
September 30, 2022
Enrollment
581 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19